Ignite Creation Date:
2024-05-06 @ 6:12 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05574881
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2022-10-05
Brief Title:
Dalpiciclib Fulvestrant Trastuzumab and Pertuzumab in HR Positive HER2 Positive Metastatic Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Organization Data
Organization:
Fudan University
Class:
OTHER
Study ID:
YOUNGBC-22
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fudan University
Lead Sponsor Class:
OTHER
Responsible Party:
Biyun Wang MD
Responsible Party Title:
Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Fudan University
Old Name:
None
Old Organization:
None